Perioperative plasma glypican-3 level may enable prediction of the risk of recurrence after surgery in patients with stage I hepatocellular carcinomaKazuya Ofuji, Tetsuya Nakatsura, Hirofumi Shirakawa et al.|Oncotarget|2016Cited by 28
Abstract 5371: Immune correlates of survival in advanced hepatocellular carcinoma patients treated with glypican-3-derived peptide vaccine: Results from phase I trialYu Sawada, Tetsuya Nakatsura, Daisuke Nobuoka et al.|Cancer Research|2012Cited by 0